New drug candidate offers hope for Treatment-Resistant depression

NCT ID NCT03870776

Completed Symptom relief Sponsor: Mapreg Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a daily oral drug called MAP4343 in 126 adults whose depression did not improve with standard antidepressants. Participants took either MAP4343 or a placebo for 6 weeks. The main goal was to see if the drug reduced depression symptoms more than placebo, measured by a standard rating scale. The study is complete, and results will show whether MAP4343 is safe and effective for this hard-to-treat group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MAP4343 (an oral drug)
What this could lead to: If it works, this could offer a new option for people with depression that doesn't respond to standard antidepressants.
What could go wrong: This is an early phase 2 trial with only 126 people, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION

Contacts and locations

Locations

APHP Hôpital La Pitié Salpétrière - Prinicipal investigator center

Paris, 75013, France
CHD Vendée

La Roche-sur-Yon, 85000, France
CHRU Tours

Tours, 37000, France
CHU Angers

Angers, 49900, France
CHU Besançon

Besançon, 25000, France
CHU Henri Laborit

Poitiers, 86000, France
CHU Nantes

Nantes, 44000, France
Cabinet Médical Ambroise Paré

Élancourt, 78990, France
Hôpital Fontan 1

Lille, 59000, France
Hôpital Ste Anne

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.